HER2 belongs to the human epidermal growth factor receptor (EGFR) family and is an oncogenic driver to be well used as the marker of prognosis and therapeutic target in ovarian [41] and breast cancers [42]; it also plays a key factor in CRC [43]. This evidence concerns the gene EGFR and breast carcinoma.